CC-99677 (BMS) is an oral, covalent MAPK–activated protein kinase-2 (MK2) inhibitor being developed for autoimmune diseases. Although p38 is the most heralded member of the p38-MAPK signaling pathway, one that mediates the release of pro-inflammatory cytokines and is implicated in several inflammatory diseases, attempts to directly [...]
4 minute read
Aug. 26, 2022
CC-99677: an Oral, Covalent MAPK–Activated Protein Kinase-2 (MK2) Inhibitor for Autoimmune Diseases
CC-99677
oral, covalent MK2 inhibitor Ph. II candidate in ankylosing spondylitis from previously disclosed MK2 inhibitor and SBDD Transl Res, June 9, 2022 Bristol Myers Squibb, Princeton, NJ
Loading...
